Citi sees up to 410% upside in 2 biotech stocks: is the risk worth it?

Impact · against what's priced in

Citi's bullish price targets provide a speculative catalyst for BMEA and SNDX, though the impact is primarily based on upcoming clinical data and compounding growth rather than a shift in fundamental consensus. BMEA faces a high-volatility event with its Q3 GLP-1 readout, while SNDX's upside is tied to the expansion of its existing commercial franchises.

BMEA+0.60: No priced-in read yet

Citi sees up to 410% upside in 2 biotech stocks: is the risk worth it?

What matters in this story

Biomea Fusion, Inc. (BMEA) Discusses BMF-650 Phase I Topline Results and Potential for Separating GI Side Effects from Weight Loss Transcript

Citi sees up to 410% upside in 2 biotech stocks: is the risk worth it?

What matters in this story

Biomea Fusion, Inc. (BMEA) Discusses BMF-650 Phase I Topline Results and Potential for Separating GI Side Effects from Weight Loss Transcript

How each ticker is affected

Track these names every morning.

Syndax Investigation Notice: SueWallSt Notifies Investors of Pending Investigation Into Syndax (SNDX)

Johnson & Johnson shares SLIDE nearly 6% despite stronger full-year forecast

UnitedHealth vs. Johnson & Johnson: Which Stock Is the Better Buy After Q3 Earnings?

Kura Oncology, Inc. (KURA) Discusses KO-7246 Data and Development Strategy for Menin Inhibitors in Diabetes Transcript

Citi sees up to 410% upside in 2 biotech stocks: is the risk worth it?

What matters in this story

Next reads from the same story arc

Biomea Fusion, Inc. (BMEA) Discusses BMF-650 Phase I Topline Results and Potential for Separating GI Side Effects from Weight Loss Transcript

Citi sees up to 410% upside in 2 biotech stocks: is the risk worth it?

What matters in this story

Next reads from the same story arc

Biomea Fusion, Inc. (BMEA) Discusses BMF-650 Phase I Topline Results and Potential for Separating GI Side Effects from Weight Loss Transcript

How each ticker is affected

Track these names every morning.

Syndax Investigation Notice: SueWallSt Notifies Investors of Pending Investigation Into Syndax (SNDX)

Johnson & Johnson shares SLIDE nearly 6% despite stronger full-year forecast

UnitedHealth vs. Johnson & Johnson: Which Stock Is the Better Buy After Q3 Earnings?

Kura Oncology, Inc. (KURA) Discusses KO-7246 Data and Development Strategy for Menin Inhibitors in Diabetes Transcript